These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15991885)

  • 1. Icatibant: HOE 140, JE 049, JE049.
    Drugs R D; 2005; 6(4):239-44. PubMed ID: 15991885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icatibant: HOE 140, JE 049, JE049.
    Drugs R D; 2004; 5(6):343-8. PubMed ID: 15563238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icatibant for hereditary angioedema.
    Gras J
    Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of icatibant (HOE-140, JE-049).
    Cruden NL; Newby DE
    Expert Opin Pharmacother; 2008 Sep; 9(13):2383-90. PubMed ID: 18710362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M; Banerji A; Bracho F; Malbrán A; Rosenkranz B; Riedl M; Bork K; Lumry W; Aberer W; Bier H; Bas M; Greve J; Hoffmann TK; Farkas H; Reshef A; Ritchie B; Yang W; Grabbe J; Kivity S; Kreuz W; Levy RJ; Luger T; Obtulowicz K; Schmid-Grendelmeier P; Bull C; Sitkauskiene B; Smith WB; Toubi E; Werner S; Anné S; Björkander J; Bouillet L; Cillari E; Hurewitz D; Jacobson KW; Katelaris CH; Maurer M; Merk H; Bernstein JA; Feighery C; Floccard B; Gleich G; Hébert J; Kaatz M; Keith P; Kirkpatrick CH; Langton D; Martin L; Pichler C; Resnick D; Wombolt D; Fernández Romero DS; Zanichelli A; Arcoleo F; Knolle J; Kravec I; Dong L; Zimmermann J; Rosen K; Fan WT
    N Engl J Med; 2010 Aug; 363(6):532-41. PubMed ID: 20818888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icatibant as acute treatment for hereditary angioedema in adults.
    Farkas H
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT.
    BioDrugs; 2003; 17(3):223-5. PubMed ID: 12749761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icatibant for the treatment of hereditary angioedema.
    Cole SW; Lundquist LM
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
    Straka BT; Ramirez CE; Byrd JB; Stone E; Woodard-Grice A; Nian H; Yu C; Banerji A; Brown NJ
    J Allergy Clin Immunol; 2017 Jul; 140(1):242-248.e2. PubMed ID: 27913306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
    Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M;
    Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
    Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.